Strategic Asset Divestment Nabriva Therapeutics is actively divesting assets, having sold rights to Contepo and Xenleta to companies like Meitheal Pharmaceuticals and Sumitomo Pharma. This strategic move indicates potential opportunities to explore partnership or licensing deals for remaining or future assets and to expand distribution channels in new markets.

Focus on Serious Infections With a portfolio centered on novel antibiotics for serious infections such as cUTIs and bacterial skin infections, Nabriva presents high-value opportunities for healthcare providers and distributors seeking innovative antimicrobial solutions for complex cases and hospital settings.

Global Market Presence Headquartered in Dublin with operational offices in Austria and the US, Nabriva’s international footprint allows for potential collaborations across multiple regions, especially in Europe and North America, where their products have already established a presence.

Recent Product Launches The launch of Xenleta in late 2021 and ongoing development of Contepo suggests opportunities to promote these products within hospital networks, specialty clinics, and infectious disease specialists looking for first-in-class treatment options.

Financial and Partnership Stability With a revenue range of 25-50 million dollars and over 90 million in funding, Nabriva demonstrates financial backing and growth potential, making it a compelling partner for distributors, licensing agreements, or collaborative sales initiatives in the antimicrobial segment.